Targeting the endothelium by combining endothelin-1 antagonism and SGLT-2 inhibition: better together?

被引：1

作者：

Ambery, Phil ^{[1
]}

Greasley, Peter J. ^{[2
]}

Menzies, Robert I. ^{[3
]}

Brynne, Lena ^{[4
]}

Kulkarni, Spoorthy ^{[5
,6
]}

Oscarsson, Jan ^{[1
]}

Davenport, Anthony P. ^{[6
]}

机构：

[1] AstraZeneca, Cardiovasc Renal & Metab, BioPharmaceut R&D, Clin Late Dev, Gothenburg, Sweden

[2] AstraZeneca, BioPharmaceut R&D, Res & Early Dev Cardiovasc Renal & Metab, Early Clin Dev, Gothenburg, Sweden

[3] AstraZeneca, BioPharmaceut R&D, Biosci Renal Res & Early Dev, Cardiovasc Renal & Metab, Gothenburg, Sweden

[4] AstraZeneca, Cardiovasc Renal & Metab, BioPharmaceut R&D, Informat Practice Late Dev, Gothenburg, Sweden

[5] Cambridge Univ Hosp NHS Fdn Trust, Dept Clin Pharmacol & Therapeut, Cambridge CB20QQ, England

[6] Univ Cambridge, Addenbrookes Hosp, Div Expt Med & Immunotherapeut, Cambridge, England

来源：

CLINICAL SCIENCE | 2024年 / 138卷 / 11期

关键词：

COTRANSPORTER; 2; INHIBITORS; RECEPTOR ANTAGONIST; ALDOSTERONE; CIRRHOSIS; DAPAGLIFLOZIN; SPARSENTAN; ZIBOTENTAN; RATIONALE; EFFICACY; DISEASE;

D O I：

10.1042/CS20240605

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

Endothelin A and B receptors, together with sodium-glucose cotransporter-2 (SGLT-2) channels are important targets in improving endothelial function and intervention with inhibitors has been the subject of multiple mechanistic and clinical outcome trials over recent years. Notable successes include the treatment of pulmonary hypertension with endothelin receptor antagonists, and the treatment of heart failure and chronic kidney disease with SGLT-2 inhibitors. With distinct and complementary mechanisms, in this review, we explore the logic of combination therapy for a number of diseases which have endothelial dysfunction at their heart.

引用

页码：687 / 697

页数：11

共 79 条

[1] Current and future strategies for targeting the endothelin pathway in cardiovascular disease
Abraham, George R.
Williams, Thomas L.
Maguire, Janet J.
Greasley, Peter J.
Ambery, Philip
Davenport, Anthony P.
[J]. NATURE CARDIOVASCULAR RESEARCH, 2023, 2 (11): : 972 - 990
[2] Endothelin-1 is increased in the plasma of patients hospitalised with Covid-19
Abraham, George R.
Kuc, Rhoda E.
Althage, Magnus
Greasley, Peter J.
Ambery, Philip
Maguire, Janet J.
Wilkinson, Ian B.
Hoole, Stephen P.
Cheriyan, Joseph
Davenport, Anthony P.
[J]. JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 2022, 167 : 92 - 96
[3] Mechanistic study of the effect of Endothelin SNPs in microvascular angina-Protocol of the PRIZE Endothelin Sub-Study
Abraham, George R.
Morrow, Andrew J.
Oliveira, Joana
Weir-McCall, Jonathan R.
Davenport, Emma E.
Berry, Colin
Davenport, Anthony P.
Hoole, Stephen P.
[J]. IJC HEART & VASCULATURE, 2022, 39
[4] Endothelin-2 Injures the Blood-Retinal Barrier and Macroglial Muller Cells Interactions with Angiotensin II, Aldosterone, and NADPH Oxidase
Alrashdi, Saeed F.
Deliyanti, Devy
Talia, Dean M.
Wilkinson-Berka, Jennifer L.
[J]. AMERICAN JOURNAL OF PATHOLOGY, 2018, 188 (03) : 805 - 817
[5] Empagliflozin in Heart Failure with a Preserved Ejection Fraction
Anker, Stefan D.
Butler, Javed
Filippatos, Gerasimos
Ferreira, Joao P.
Bocchi, Edimar
Boehm, Michael
Brunner-La Rocca, Hans-Peter
Choi, Dong-Ju
Chopra, Vijay
Chuquiure-Valenzuela, Eduardo
Giannetti, Nadia
Gomez-Mesa, Juan Esteban
Janssens, Stefan
Januzzi, James L.
Gonzalez-Juanatey, Jose R.
Merkely, Bela
Nicholls, Stephen J.
Perrone, Sergio V.
Pina, Ileana L.
Ponikowski, Piotr
Senni, Michele
Sim, David
Spinar, Jindrich
Squire, Iain
Taddei, Stefano
Tsutsui, Hiroyuki
Verma, Subodh
Vinereanu, Dragos
Zhang, Jian
Carson, Peter
Lam, Carolyn Su Ping
Marx, Nikolaus
Zeller, Cordula
Sattar, Naveed
Jamal, Waheed
Schnaidt, Sven
Schnee, Janet M.
Brueckmann, Martina
Pocock, Stuart J.
Zannad, Faiez
Packer, Milton
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (16) : 1451 - 1461
[6] Antifibrotic effect and long-term outcome of SGLT2 inhibitors in patients with NAFLD complicated by diabetes mellitus
Arai, Taeang
Atsukawa, Masanori
Tsubota, Akihito
Mikami, Shigeru
Haruki, Uojima
Yoshikata, Keiichiro
Ono, Hiroki
Kawano, Tadamichi
Yoshida, Yuji
Tanabe, Tomohide
Okubo, Tomomi
Hayama, Korenobu
Nakagawa-Iwashita, Ai
Itokawa, Norio
Kondo, Chisa
Kaneko, Keiko
Nagao, Mototsugu
Inagaki, Kyoko
Fukuda, Izumi
Sugihara, Hitoshi
Iwakiri, Katsuhiko
[J]. HEPATOLOGY COMMUNICATIONS, 2022, 6 (11) : 3073 - 3082
[7] Endothelin: 30 Years From Discovery to Therapy
Barton, Matthias
Yanagisawa, Masashi
[J]. HYPERTENSION, 2019, 74 (06) : 1232 - 1265
[8] Medical progress - Coronary microvascular dysfunction
Camici, Paolo G.
Crea, Filippo
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (08) : 830 - 840
[9] Practical Considerations for the Use of Sparsentan in the Treatment of Patients with IgAN in Clinical Practice
Campbell, Kirk N.
Griffin, Sian
Trachtman, Howard
Geletka, Rob
Wong, Muh Geot
[J]. INTERNATIONAL JOURNAL OF NEPHROLOGY AND RENOVASCULAR DISEASE, 2023, 16 : 281 - 291
[10] Persistent complement dysregulation with signs of thromboinflammation in active Long Covid
Cervia-Hasler, Carlo
Brueningk, Sarah C.
Hoch, Tobias
Fan, Bowen
Muzio, Giulia
Thompson, Ryan C.
Ceglarek, Laura
Meledin, Roman
Westermann, Patrick
Emmenegger, Marc
Taeschler, Patrick
Zurbuchen, Yves
Pons, Michele
Menges, Dominik
Ballouz, Tala
Cervia-Hasler, Sara
Adamo, Sarah
Merad, Miriam
Charney, Alexander W.
Puhan, Milo
Brodin, Petter
Nilsson, Jakob
Aguzzi, Adriano
Raeber, Miro E.
Messner, Christoph B.
Beckmann, Noam D.
Borgwardt, Karsten
Boyman, Onur
[J]. SCIENCE, 2024, 383 (6680) : 1 - 18

← 1 2 3 4 5 6 7 8 →